Therapeutic effects of LDL apheresis in the prevention of atherosclerosis

Current Opinion in Lipidology

Volumn 10, Issue 5, 1999, Pages 401-406

  Kajinami, Kouji ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULOSE; DEXTRAN SULFATE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN;

APHERESIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; BLOOD COMPONENT REMOVAL; CLINICAL TRIALS; HUMANS; LIPOPROTEINS, LDL; TREATMENT OUTCOME;

EID: 0033380221     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199910000-00004     Document Type: Review

References (37)

1. 1 Braunwald E. Shattuck lecture. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337:1360-1369.
2. 2 Mabuchi H. Use of LDL-apheresis in the management of familial hypercholesterolemia. Curr Opin Lipidol 1990; 1:43-47.
3. 3 Demant T, Seidel D. Recent development in low-density lipoprotein apheresis. Curr Opin Lipidol 1992; 3:43-48.
4. 4 Gordon BR, Saal SD. Advances in LDL-apheresis for the treatment of severe hypercholesterolemia. Curr Opin Lipidol 1994; 5:69-73.
5. 5 Gordon BR, Saal SD. Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol 1996; 7:381-384.
6. 6 Thiery J, Seidel D. Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Curr Opin Lipidol 1998; 9:521-526.
7. 7 Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992; 95:1-13.
8. 8 Schuff-Werner P, Gohlke U, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease. Eur J Clin Invest 1994; 24:724-732.
9. 9 Waidner T, Franzen D, Voelker W, Ritter M, Borberg H, Hombach V, Höpp HW, and the LDL Apheresis Study Group. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Result of a multicenter LDL apheresis study. Clin Invest 1994; 72:858-863.
10. 10 Thompson GR, Maher VMG, Mathews S, Kitano Y, Nenwirth C, Shortt MB, et al. Familial Hypercholesterolemia Regression Study: a randomized trial of low-density lipoprotein apheresis. Lancet 1995; 345:811-816.
11. 11 Kroon AA, Aengevaeren WRM, van der Werf T, Uijen GNH, Reiber JHC, Bruschke AVG, Atalenhoef AFH. LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of agressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93:1826-1835.
12. 12 Richter WO, Donner MG, Hfling B, Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998; 47:863-868. This is an open trial, with the longest period of follow-up, and describes the results of weekly treatment using HELP system with a relatively short period.
13. 13 Park JW, Merz M, Braun P. Effects of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. Atherosclerosis 1998; 139:401-409. This study described alterations of clinical status of ischemic symptoms after apheresis therapy in addition to angiographic outcomes.
14. 14 Gordon BR, Kelsey SF, Dau PC, Gotto AM Jr, Graham K, Illingworth R, et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1998; 81:407-411. This is one of two landmark studies investigating the long-term effects of LDL apheresis on future cardiovascular events in patients with familial hypercholesterolemia, which was conducted in multicenter in the USA. During apheresis therapy, the cardiovascular event rate was nearly half that during the control period receiving drug therapy alone.
15. 15 Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T, and the Hokuriku-FH-LDL-Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998; 82:1489-1495. This is the first case - control study demonstrating long-term beneficial effects of LDL apheresis in patients with both familial hypercholesterolemia and angiographically defined coronary artery disease. LDL apheresis with DSC columns (43 patients) dramatically reduced cardiac events by 72% during 6.0 years of follow-up, compared to treatment with drugs alone (87 patients).
16. 16 Nishimura S, Yamaguchi H. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan LDL-Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999; in press.
17. 17 Saku K, Takeda Y, Jimi S, Okabe M, Shirai K, Nii T, et al. Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography. J Cardiol 1998; 31:239-245.
18. 18 Mii S, Mori A, Sakata H, Nakayama M, Tsuruta H. LDL apheresis for arteriosclerosis obliterans with occluded bypass graft: changes in prostacyclin and effect on ischemic symptoms. Angiology 1998; 49:175-180. Intensive LDL apheresis for patients with lower limb ischemia resulted in a favorable outcome, which was associated with significant alterations of prostacyclin production.
19. 19 Kroon AA, van der Asten WNJC, Stalenhoef AFH. Effect of apheresis on low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996; 125:945-954.
20. 20 Koga N. The retardation of progressin, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. Therap Apher 1997; 1:260-270.
21. 21 Hennerici M, Kleophas W, Gries FA Regression of carotid plaques during low density lipoprotein cholesterol elimination. Stroke 1991; 22:989-992.
22. 22 Aengevaeren WR, Kroon AA, Stalenhoef AF, Uijen GJ, van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996; 28:1696-1704.
23. 23 Stadler RW, Ibrahim SF, Lees RS. Peripheral vasoreactivity in familial hypercholesterolemic subjects treated with heparin-induced extracorporeal LDL-precipitation (HELP). Atherosclerosis 1997; 128:241-249.
24. 24 Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997; 95:76-82.
25. 25 Mellwig KP, Baller D, Gleichmann U, Moll D, Betker S, Weise R, Notohamiprodjo G. Improvement of coronary vasodilatation capacity through single apheresis. Atherosclerosis 1998; 139:173-178. This recent study provided the first evidence suggesting that single LDL apheresis therapy can improve coronary vasodilation capacity as assessed by PET.
26. 26 Meyer C, Geiss HC, Duvemoy CS, Parhofer KG, Schwandt P. Myocardial perfusion before and after single routine LDL-apheresis. J Am Coll Cardiol 1998; 31 (Suppl A): 23A. This study demonstrated that single apheresis did not produce significant alterations in myocardial perfusion and vasodilatory capacity in patients treated with weekly LDL apheresis.
27. 27 Koizumi J, Koizumi I, Uno Y, Inazu A, Kajinami K, Haraki T, et al. Reduction of lipoprotein (a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 1993; 100:65-74.
28. 28 Banyai S, Streicher J, Strobl W, Gabriel H, Gottsauner-Wolf M, Rohac M, et al. Therapeutic efficiency of lipoprotein (a) reduction by low-density lipoprotein immunoapheresis. Metabolism 1998; 47:1058-1064.
29. 29 Napoli C, Ambrosio G, Scarpato N, Corso G, Palumbo G, D'Armiento FP, et al. Decreased low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Am Heart J 1997; 133:585-595.
30. 30 Uno H, Ueki Y, Murashima J, Miyake S, Tominaga Y, Eguchi K, Yano K. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterance. Atherosclerosis 1995; 116:93-102.
31. 31 Sampietro T, Tuoni M, Ferdeghini M, Ciardi A, Marraccini P, Prontera C, et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 1997; 96:1381-1385.
32. 32 Rovers C, Netea MG, de Bont N, Demacker PNM, Jacobs C, Kullberg BJ, et al. LPS-induced cytokine production and expression of §2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis 1998; 141:99-105.
33. 33 Mabuchi H, Fujita H, Michishita I, Takeda M, Kajinami K, Koizumi J, et al. Effects of CS-514, and inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis. Atherosclerosis 1988; 72:183-188.
34. 34 Geiss HC, Parhofer G, Schwandt P. Atorvastatin compared with simvastatin in patients with severe hypercholesterolemia treated by regular LDL apheresis. J Intern Med 1999; 245:47-55. Currently the most potent statin available, atorvastatin, produced a significant reduction when substituted for simvastatin in patients receiving regular apheresis therapy.
35. 35 Suckfüll M, Thiery J, Wimmer C, Mees K, Schorn K. Hypercholesterolemia and hyperfibrinogenemia in sudden deafness. Laryngorhinootologie 1997; 76:453-457.
36. 36 Kobayashi S. LDL-apheresis for diabetic nephropathy: a possible new tool. Nephron 1998; 79:505-506. This case study described a favorable effect of LDL apheresis (six procedures) on massive proteinuria, which is probably due to diabetic nephropathy.
37. 37 Dräger LJ, Julius U, Kraenzle K, Schaper J, Toepfer M, Zygan K, et al. DALI - the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 1998; 28:994-1002. The procedural and clinical results of newly developed whole-blood LDL apheresis system are described.